DK1176963T3 - Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser - Google Patents

Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser

Info

Publication number
DK1176963T3
DK1176963T3 DK00927101T DK00927101T DK1176963T3 DK 1176963 T3 DK1176963 T3 DK 1176963T3 DK 00927101 T DK00927101 T DK 00927101T DK 00927101 T DK00927101 T DK 00927101T DK 1176963 T3 DK1176963 T3 DK 1176963T3
Authority
DK
Denmark
Prior art keywords
dopamine
drugs
manufacture
treatment
receptor antagonists
Prior art date
Application number
DK00927101T
Other languages
English (en)
Inventor
Dorothea Starck
Hans-Joerg Treiber
Bernd Muehlbauer
Gerhard Gross
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of DK1176963T3 publication Critical patent/DK1176963T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00927101T 1999-05-07 2000-04-28 Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser DK1176963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
PCT/EP2000/003865 WO2000067847A2 (de) 1999-05-07 2000-04-28 Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen

Publications (1)

Publication Number Publication Date
DK1176963T3 true DK1176963T3 (da) 2005-04-25

Family

ID=7908194

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00927101T DK1176963T3 (da) 1999-05-07 2000-04-28 Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser

Country Status (19)

Country Link
US (2) US7098214B1 (da)
EP (1) EP1176963B1 (da)
JP (3) JP4727822B2 (da)
KR (2) KR20010112474A (da)
CN (2) CN101524356A (da)
AT (1) ATE284693T1 (da)
AU (1) AU770671B2 (da)
BR (1) BR0010337A (da)
CA (1) CA2368823C (da)
CZ (1) CZ301832B6 (da)
DE (2) DE19922443A1 (da)
DK (1) DK1176963T3 (da)
ES (1) ES2234597T3 (da)
HU (1) HU228516B1 (da)
IL (2) IL146232A0 (da)
NO (1) NO329325B1 (da)
PT (1) PT1176963E (da)
WO (1) WO2000067847A2 (da)
ZA (1) ZA200110044B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
EP1223932A4 (en) 1999-10-01 2003-01-15 Smithkline Beecham Corp COMPOUNDS AND METHODS
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
DE60208157T2 (de) 2001-02-16 2006-08-10 Aventis Pharmaceuticals Inc. Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
EP1688412A3 (en) * 2001-02-16 2006-08-16 Aventis Pharmaceuticals, Inc. Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
DE60216753T2 (de) * 2001-02-16 2008-01-03 Aventis Pharmaceuticals Inc. Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
EP1381360A4 (en) * 2001-03-29 2009-12-02 Smithkline Beecham Corp COMPOUNDS AND METHODS FOR INHIBITING METAP2 IN MAMMALS
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
EP1471818A4 (en) * 2002-02-04 2007-03-28 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES
EP1606633B1 (en) * 2003-03-17 2008-06-04 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
ATE452134T1 (de) * 2004-08-09 2010-01-15 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
EP1812416B1 (en) 2004-10-14 2013-08-21 Abbott GmbH & Co. KG Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
EP1809597B1 (en) 2004-10-14 2012-01-11 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
MX2007004355A (es) 2004-10-14 2007-07-17 Abbot Gmbh & Co Kg Compuestos de 6-amino (aza) indano adecuados para tratar trastornos que responden a la modulacion del receptor de dopamina d3.
WO2006040182A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
EP2004166A2 (en) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2008016171A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Agent prophylactique/thérapeutique destiné à un dysfonctionnement rénal
WO2009093471A1 (ja) * 2008-01-25 2009-07-30 Nihon University アポトーシス抑制薬
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (da) * 1962-12-26
US3290004A (en) * 1965-04-09 1966-12-06 Hitachi Ltd Device for damping vibration of long steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
HU228516B1 (en) 2013-03-28
HUP0202399A2 (hu) 2002-12-28
HUP0202399A3 (en) 2003-02-28
WO2000067847A3 (de) 2001-08-02
ZA200110044B (en) 2003-03-06
DE19922443A1 (de) 2000-11-09
ES2234597T3 (es) 2005-07-01
PT1176963E (pt) 2005-05-31
BR0010337A (pt) 2002-02-13
NO20015413L (no) 2001-11-15
EP1176963B1 (de) 2004-12-15
CA2368823C (en) 2008-10-21
KR100781828B1 (ko) 2007-12-03
NO329325B1 (no) 2010-09-27
JP2002544178A (ja) 2002-12-24
ATE284693T1 (de) 2005-01-15
IL146232A0 (en) 2002-07-25
KR20010112474A (ko) 2001-12-20
JP2011088941A (ja) 2011-05-06
JP4727822B2 (ja) 2011-07-20
EP1176963A2 (de) 2002-02-06
CZ301832B6 (cs) 2010-07-07
DE50008964D1 (de) 2005-01-20
US8785447B2 (en) 2014-07-22
JP5897054B2 (ja) 2016-03-30
CZ20014015A3 (cs) 2002-02-13
JP5542713B2 (ja) 2014-07-09
CN1360502A (zh) 2002-07-24
US20060223793A1 (en) 2006-10-05
CN1360502B (zh) 2010-08-04
AU4559100A (en) 2000-11-21
WO2000067847A2 (de) 2000-11-16
US7098214B1 (en) 2006-08-29
CN101524356A (zh) 2009-09-09
NO20015413D0 (no) 2001-11-06
AU770671B2 (en) 2004-02-26
KR20070040425A (ko) 2007-04-16
CA2368823A1 (en) 2000-11-16
IL146232A (en) 2007-06-03
JP2014098044A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
DK1176963T3 (da) Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
BG108491A (en) 5-ht receptor ligands and uses thereof
GB0504828D0 (en) Therapeutic agents
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
ATE389404T1 (de) Kappa-opioid-rezeptor-liganden
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
ATE433966T1 (de) Methylendipiperidinderivate
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60305063D1 (de) Ccr1-rezeptor-antagonisten zur behandlung u.a. demyelinisierender entzündlicher erkrankungen
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
DE60314896D1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
DK2001456T3 (da) Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
PT1143942E (pt) Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas
DK1503764T3 (da) 5-HT4-receptor-antagonister til behandling af hjertesvigt
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia
UA97251C2 (ru) Соединения как модуляторы опиоидного рецептора